ArticleScientific reports2019
The Immunogenicity of OMP31 Peptides and Its Protection Against Brucella melitensis Infection in Mice.
Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 29 citations in OpenAlex.
- Brucellosis vaccine development: immunological mechanisms, animal models, and future directions.Archives of microbiology · 2026Review
- Phylogeny-guided multi-epitope vaccine design targeting conserved and divergent regions of Brucella OMP2, OMP25, and OMP31: an immunoinformatics study.BMC immunology · 2026Article
- Multiepitope fusion protein-based ELISA for enhanced brucellosis serodiagnosis.PLoS neglected tropical diseases · 2025Article
- Development and evaluation of multiepitope fusion proteins for serological diagnosis of animal brucellosis.Microbiology spectrum · 2025Article
- Design of a multi-Epitope mRNA vaccine against Brucella type IV secretion system using reverse vaccinology and immunogenicity approaches.Scientific reports · 2025Article
- The Lpp-OmpA-BtaE fusion protein causes a protective immune response against Brucella melitensis in mice.Scientific reports · 2025Article
- Design of a multi-epitope recombinant BCG vaccine targeting Brucella OMP31, LptE and VirB2 in immunoinformatics approaches.PloS one · 2025Article
- Bioinformatics approach for structure modeling, vaccine design, and molecular docking of Brucella candidate proteins BvrR, OMP25, and OMP31.Scientific reports · 2024Article
- Immunoinformatics analysis of Brucella melitensis to approach a suitable vaccine against brucellosis.Journal, genetic engineering & biotechnology · 2023Article
- Exosomes released by Brucella-infected macrophages inhibit the intracellular survival of Brucella by promoting the polarization of M1 macrophages.Microbial biotechnology · 2023Article
- Safe Subunit Green Vaccines Confer Robust Immunity and Protection against Mucosal Brucella Infection in Mice.Vaccines · 2023Article
- Design of multi-epitope vaccine candidate against Brucella type IV secretion system (T4SS).PloS one · 2023Article
- Design of a multi-epitope vaccine candidate against Brucella melitensis.Scientific reports · 2022Article
- Design of a Recombinant Multivalent Epitope Vaccine Based on SARS-CoV-2 and Its Variants in Immunoinformatics Approaches.Frontiers in immunology · 2022Article
- Evaluation of the Combined Use of Major Outer Membrane Proteins in the Serodiagnosis of Brucellosis.Infection and drug resistance · 2022Article
- Evaluation of Brucellosis Vaccines: A Comprehensive Review.Frontiers in veterinary science · 2022Review
- Design of a new multi-epitope vaccine againstEpidemiology and infection · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Given brucellosis is a widespread zoonosis in the world, a safe and effective vaccine is urgently needed. Recent trend in vaccine design has shifted to epitope-based vaccines that are safe and specific. In this study, peptide containing both T-cell and B-cell epitopes of OMP31 was synthesized and used to immunize the mice by nasal administration. The protective efficacy was evaluated. Mice immunized with the B epitope or TB epitope peptides of OMP31 had higher levels of IgG1 and IgG2a in the serum. While the BALB/c mice immunized with peptides containing T cell epitope or TB epitope of OMP31 showed high degree of IFN-γ-producing T cells in the lymphocytes from the respiratory draining lymph nodes and spleen. After intranasally challenged with 5 × 10
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.